• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Disease modeling

Studying disease models gives an understanding of how a disease develops, offering insight into potential treatment approaches and responses to drug candidates

Current industry methods

Current in vitro disease models do not fully represent the scope and symptoms of a disease.

Most models are short-term (up to seven days) and limited to a single immortalized cell type, making them unable to functionally mimic the properties of an organ.

Advancements with PhysioMimix®

PhysioMimix allows you to create complex and physiologically relevant models that accurately express the disease phenotype.

More complete disease models generate clinically translatable data to prevent unexpected results in the clinic.

Multi-well plates

Metabolic dysfunction-associated steatohepatitis


Liver disease is a major health problem worldwide accounting for approximately two million deaths annually. A proportion of deaths due to Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more advanced stage, Metabolic dysfunction-associated steatohepatitis (MASH) are preventable.

With anti-MASH therapeutics failing to pass clinical trials, a new preclinical test is required to improve human efficacy predictions. Our MSLD/MASH application provides a pre-clinical in vitro model using human tissue to fully replicate this critical liver disease phenotype.

Learn more
LC12 plates

Hepatitis B


Hepatitis B (HBV) is a human-specific hepatotropic virus that increases the risk of terminal liver disease. The specificity of the disease reduces the number of suitable models available for research and therapeutic development.

CN Bio has developed perfused human hepatocytes cultured in 3D as a preclinical tool to study the HBV life cycle and novel therapeutics in the human liver.

Learn more
LC12 plate, tube and pipette

Pulmonary infection


The lung is extremely vulnerable to infection and injury due to constant exposure to inhaled particles and pathogens in the environment. Respiratory diseases are a leading cause of death globally which has been exacerbated by the COVID-19 pandemic.

With only 3% of new pulmonary therapeutics reaching the market, there is a need for innovative preclinical models which can accurately mimic the human lung and predict responses to infection and novel therapeutics.

Learn more

Jump to area of interest

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
Cyber Essentials Logo